Skip to content

PHARMADVANCE

Active Private limited companyfounded 2017active for 9 yearsRue de l'Eglise 48, 7950 ChièvresKBO/BCE: BE 0671.818.337 #3 company by total assets in Chièvres, Wholesale and retail trade sector

Lifetime

9 annual accounts with figures on one time axis
peak of €344,477 in 2021
€299,297▼ 8.9%
lowest -€136,995 in 2017
€43,820▲ 280%
peak of €91,136 in 2025
€91,136▲ 53.6%
€975,360▼ 5.7%
peak of 4.1 FTE in 2022
4 FTE▲ 5.3%
Board2 names since 2017
2 directors and 1 other
Owners
  
Documentsfilings and deeds
08-07-202623 days before the deadline
2025abbreviated format
Result from €11,539 to €43,820Equity from €59,315 to €91,136Cash from €10,185 to €49,161

Key points

from the 2025 annual accounts

Equity

€91,136 ▲ 53.6%

PHARMADVANCE has made a profit without a break since 2020.

Turnover

≈ €1.0m estimated

The accounts state no turnover.

Debts

€975,360 91% of the balance sheet
Financial debts 26%Suppliers 46%Taxes and wages 4%Other 24%

Of this, €726,360 falls due within a year.

Filings

9 annual accounts 8 late
AprilJune31 JulyOctober20202025

The 2022 accounts came in latest, 90 days after the end of the period.

Position in the sector

8.5%

Lower solvency than 82% of companies in retail trade. The sector median is 36.8%, over 13,315 companies.

Checked score

Bankruptcy probability within 12 months

Financial strength

Score breakdown

Comparable companies, two years later

In July 2024, 1,250 companies had the same profile as PHARMADVANCE has now. Each dot stands for 4 companies, two years later.

94.4%
were still trading
2.7%
stopped another way
2.7%
went bankrupt
  • Micro
  • 5 to 10 years old
  • solvency under 10%
  • a profit under 5% of the balance sheet

Another 0.2% stopped without a precise date, possibly only after those two years.

Test of the method

The method was tested on the 497,894 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.7% would go bankrupt within 24 months. In fact 1.8% went bankrupt.

The companies in ten equal groups, from the lowest to the highest expected share
Group Expected Actual
1 0.2% 0.2%
2 0.4% 0.5%
3 0.6% 0.6%
4 0.7% 0.8%
5 0.9% 1.0%
6 1.4% 1.6%
7 1.7% 1.8%
8 1.9% 2.0%
9 3.1% 3.3%
10 5.9% 6.4%

A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.

This is an observation about 1,250 companies, not a prediction for PHARMADVANCE. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.

Credit verdict

Credit check for an amount and term of your choice

Show the recommended maximum and see how the verdict changes with amount, term and advance.

The scores and ratios are Checked's own calculations, not a credit decision.

Signals

Board and ownership

Director, , since 16-06-2022
Director, , since 16-06-2022
  • founderdeed of 28-02-2017
  • founderdeed of 28-02-2017
Board & ownership

Recent changes

Registered in the Peppol Directory Reachable for e-invoices through 0208:0671818337
(director) and (director) change roles and act as permanent representatives · “1) l'exploitation d'officines pharmaceutiques dans le respect des règles édictées par l'Ordre des Pharmaciens…” (deed in French) · Discharge granted to · General meeting of 10-07-2023 · Gazette deed
2 directors appointed, 2 resignations and resign · and act as permanent representatives · and appointed · General meeting of 16-06-2022 · Gazette deed
New establishment in Leuze-en-Hainaut Pharmacie de la Grand-Place, Grand-Place 15
All 17 events

Comparable companies

same main activity, similar in size and age
Company
PHARMADVANCE Chièvres €1.1m €299,297 8.5% 4
PHARMACIE KERKOVRE Comblain-au-Pont €0.9m €356,053 11.7% 3.8
Mentover Antwerp €1.0m €360,699 4.6% 3.2
PHARMACIE DE l'EDEN Montigny-le-Tilleul €1.0m €394,694 46.7% 3.5
Pharmaplus Grand Place Tournai €0.9m €426,998 32.3% 3.9
PHARMACIE DEPREZ Charleroi €1.5m €306,093 41.3% 3.2
PHARMACIE LAMBLIN-LAMBOT Chapelle-lez-Herlaimont €1.3m €385,076 43.8% 4

These companies have the same main activity as PHARMADVANCE: retail sale of pharmaceutical products (NACE 47730). They are comparable in size and age: total assets between €896,000 and €1.5m, founded between 2016 and 2019.

Official details

Source: KBO
Status
Active since 24-02-2017Normal situation
Activity
Retail sale of pharmaceutical productsNACE 47730
Establishment units
2.262.124.5287950 Chièvres, since 24-02-2017
2.273.198.9587900 Leuze-en-Hainaut, since 01-05-2017
Financial year end
31 December
Peppol
Reachable since 24-11-2023
Company details

Annual accounts 2025

€1.1m▼ 2.5%
Employeeson 31-12-2025
4=
Filing
Filed on 08-07-2026, 23 days before the end of the filing period
Financials

Insights on PHARMADVANCE

PHARMADVANCE files the abbreviated format. That format states no turnover. The gross margin rose from €133,526 in 2017 to €299,297 in 2025.

Sources: KBO register, filings at the National Bank, Belgian Official Gazette. Click a figure with a dotted line for the item and the filing.

Key facts about PHARMADVANCE

What is the company number of PHARMADVANCE?
The company number of PHARMADVANCE is 0671.818.337. The VAT number is the same number with BE in front: BE 0671.818.337.
Where is PHARMADVANCE based?
The registered office is at Rue de l'Eglise 48, 7950 Chièvres.Company details
What does PHARMADVANCE do?
According to the KBO register, the main activity is retail sale of pharmaceutical products (NACE 47730).
What is the legal form of PHARMADVANCE?
PHARMADVANCE is a private limited company (BV).
When was PHARMADVANCE founded?
PHARMADVANCE was founded on 24-02-2017.
Is PHARMADVANCE still active?
Yes, PHARMADVANCE is an active enterprise in the KBO register.
How many employees does PHARMADVANCE have?
PHARMADVANCE had an average of 4 full-time equivalents in financial year 2025, according to the filed annual accounts.Financials
What is the turnover of PHARMADVANCE?
The turnover in financial year 2025 is about €1.0m. This figure is estimated from the gross margin of €299,297 and 42 comparable companies (NACE 477). It probably lies between €810,000 and €1.4m.
Is PHARMADVANCE profitable?
In financial year 2025, PHARMADVANCE made a profit of €43,820.
Where can I find the annual accounts of PHARMADVANCE?
PHARMADVANCE filed 9 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
When are the next annual accounts of PHARMADVANCE due?
PHARMADVANCE must file the annual accounts for financial year 2026 by 31-07-2027.Timeline

Next steps

See how customers, suppliers and banks see your own company and what to improve first.

Keep this company with today's facts in a case file.